Tag:
Innocoll
Latest Headlines
Latest Headlines
ALSO NOTED: Cell Therapeutics to bypass interim analysis; Nabi reports NicVAX data; Chinese see value in scientific failure; an
> Cell Therapeutics has decided to bypass an interim analysis of its non-Hodglin's lymphoma drug candidate Pixantrone. Instead, researchers say they will conduct a full analysis after the trial
